Cargando…

Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate

Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical prac...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Dohyeong, Yun, Byung Cheol, Seo, Kwang Il, Han, Byung Hoon, Lee, Sang Uk, Park, Eun Taek, Lee, Jin Wook, Jeong, Joonho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922420/
https://www.ncbi.nlm.nih.gov/pubmed/31852136
http://dx.doi.org/10.1097/MD.0000000000018351
_version_ 1783481335038345216
author Lee, Dohyeong
Yun, Byung Cheol
Seo, Kwang Il
Han, Byung Hoon
Lee, Sang Uk
Park, Eun Taek
Lee, Jin Wook
Jeong, Joonho
author_facet Lee, Dohyeong
Yun, Byung Cheol
Seo, Kwang Il
Han, Byung Hoon
Lee, Sang Uk
Park, Eun Taek
Lee, Jin Wook
Jeong, Joonho
author_sort Lee, Dohyeong
collection PubMed
description Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical practice. We completed a retrospective review of patients with CHB treated with TDF initially at Kosin University Gospel Hospital, Busan, Korea from January 2012 to January 2017. Subclinical hypophosphatemia and hypophosphatemia were defined as serum phosphorus below 3.0 mg/dL and 2.5 mg/dL, respectively. We screened 206 patients with CHB treated with TDF, among which 135 were excluded for the following reasons: baseline malignancy (59), limited data (50), co-administered other antivirals (14), hypophosphatemia at baseline (7), and other reasons (5). The final study population comprised 71 patients. Subclinical hypophosphatemia developed in 43 (60.5%) patients. Hypophosphatemia occurred in 18 patients (25.3%). Liver cirrhosis was the most significant predictor of hypophosphatemia (P = .038, OR = 3.440, CI = 1.082–10.937) Patients diagnosed with subclinical hypophosphatemia were encouraged to increase their intake of nuts and dairy products (25 patients) or reduce their alcohol intake (2), dose reduction of TDF (4) or placed under observation (4). Among patients with subclinical hypophosphatemia, serum phosphorus concentrations were elevated (>3.0 mg/dL) in 23 of 36 patients (63.8%). Increased nut and dairy intake increased phosphorus concentrations to more than 3.0 mg/dl in 16 of 25 patients (64.0%). Entecavir or tenofovir alafenamide fumarate (TAF) should be considered rather than TDF in patients with liver cirrhosis because of the risk of hypophosphatemia. Instead of stopping TDF treatment, encouraging increased intake of phosphorus-rich foods could increase serum phosphorus concentrations in clinical practice.
format Online
Article
Text
id pubmed-6922420
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-69224202020-01-23 Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate Lee, Dohyeong Yun, Byung Cheol Seo, Kwang Il Han, Byung Hoon Lee, Sang Uk Park, Eun Taek Lee, Jin Wook Jeong, Joonho Medicine (Baltimore) 4500 Tenofovir disoproxil fumarate (TDF) is thought to cause varying degrees of hypophosphatemia in patients with chronic hepatitis B (CHB). Therefore, we investigated factors that cause hypophosphatemia in patients treated with TDF and methods to increase serum phosphorus concentrations in clinical practice. We completed a retrospective review of patients with CHB treated with TDF initially at Kosin University Gospel Hospital, Busan, Korea from January 2012 to January 2017. Subclinical hypophosphatemia and hypophosphatemia were defined as serum phosphorus below 3.0 mg/dL and 2.5 mg/dL, respectively. We screened 206 patients with CHB treated with TDF, among which 135 were excluded for the following reasons: baseline malignancy (59), limited data (50), co-administered other antivirals (14), hypophosphatemia at baseline (7), and other reasons (5). The final study population comprised 71 patients. Subclinical hypophosphatemia developed in 43 (60.5%) patients. Hypophosphatemia occurred in 18 patients (25.3%). Liver cirrhosis was the most significant predictor of hypophosphatemia (P = .038, OR = 3.440, CI = 1.082–10.937) Patients diagnosed with subclinical hypophosphatemia were encouraged to increase their intake of nuts and dairy products (25 patients) or reduce their alcohol intake (2), dose reduction of TDF (4) or placed under observation (4). Among patients with subclinical hypophosphatemia, serum phosphorus concentrations were elevated (>3.0 mg/dL) in 23 of 36 patients (63.8%). Increased nut and dairy intake increased phosphorus concentrations to more than 3.0 mg/dl in 16 of 25 patients (64.0%). Entecavir or tenofovir alafenamide fumarate (TAF) should be considered rather than TDF in patients with liver cirrhosis because of the risk of hypophosphatemia. Instead of stopping TDF treatment, encouraging increased intake of phosphorus-rich foods could increase serum phosphorus concentrations in clinical practice. Wolters Kluwer Health 2019-12-16 /pmc/articles/PMC6922420/ /pubmed/31852136 http://dx.doi.org/10.1097/MD.0000000000018351 Text en Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 4500
Lee, Dohyeong
Yun, Byung Cheol
Seo, Kwang Il
Han, Byung Hoon
Lee, Sang Uk
Park, Eun Taek
Lee, Jin Wook
Jeong, Joonho
Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title_full Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title_fullStr Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title_full_unstemmed Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title_short Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
title_sort risk factors associated with hypophosphatemia in chronic hepatitis b patients treated with tenofovir disoproxil fumarate
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6922420/
https://www.ncbi.nlm.nih.gov/pubmed/31852136
http://dx.doi.org/10.1097/MD.0000000000018351
work_keys_str_mv AT leedohyeong riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT yunbyungcheol riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT seokwangil riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT hanbyunghoon riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT leesanguk riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT parkeuntaek riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT leejinwook riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate
AT jeongjoonho riskfactorsassociatedwithhypophosphatemiainchronichepatitisbpatientstreatedwithtenofovirdisoproxilfumarate